Table of Contents
<< Previous Issue | Nov 2023 (Vol: 2023, Issue: 11) | Next Issue >> |
- Section: Licensing
-
GSK Gains Rights to Janssen’s Hepatitis B Therapy JNJ-3989 for US$1 B
-
Merck KGaA Partners with Hengrui Pharma for Selective PARP1 Inhibitor and Antibody-Drug
-
Novartis Pays US$100 M Upfront for Legend Biotech’s CAR-T Cell Therapies
- Section: Mergers & Acquisitions
-
Basilea Pays US$37 M Upfront for Antifungal from Pfizer’s Amplyx
-
Merck & Co. to Acquire Caraway Therapeutics for Up to US$610 M
- Section: Research & Development
-
Merck & Co. Pays Daiichi Sankyo US$4 B Upfront for Cancer ADCs